Local view for "http://purl.org/linkedpolitics/eu/plenary/2001-10-04-Speech-4-035"
Predicate | Value (sorted: default) |
---|---|
rdf:type | |
dcterms:Date | |
dcterms:Is Part Of | |
dcterms:Language | |
lpv:document identification number |
"en.20011004.2.4-035"2
|
lpv:hasSubsequent | |
lpv:speaker | |
lpv:spokenAs | |
lpv:translated text |
"Mr President, Commissioner, ladies and gentlemen, I think that the common feature of all the statements made in this debate so far is the belief that investment in healthcare is extremely worthwhile and is an important way of achieving sustainable development and combating poverty, which are two objectives of European development policy. It is a proven fact that countries with a high standard of health and generous investment in this area achieve higher levels of development, including economic development. Some of us have already observed that we must persuade the governments in these countries to spend more on this area of healthcare and education, and I naturally underline this political demand as well.
Yet it would be cynical in the extreme if we failed to point out that the structural adjustment programmes which must be undertaken by these countries to secure loans and funding from the international financial institutions now require them to spend less on prevention, public health and education. One point which is very important, in my view, is the involvement of women in devising birth control programmes and other reproductive health campaigns. Women – and I am not saying anything new – are extremely vulnerable to poverty. Furthermore, as the HIV/AIDS infection rates in southern Africa show, women are also affected by this disease to a far greater extent than men.
Finally, I should like to say a few words about one of the most pressing issues addressed in the Khanbhai report, namely the Agreement on Trade Related Aspects of Intellectual Property Rights (TRIPS). I believe that in future, too, the European Union must assist the developing countries to benefit from the opportunities already afforded by the TRIPS agreement. Naturally, this is set forth in the provisions of the TRIPS agreement, but has not always been accepted by the pharmaceutical industry, as the case of South Africa shows. In my view, the proposal outlined in paragraph 41 of the Khanbhai report on reducing the period of patent protection is essential. I believe that when we talk about poverty, we must also identify tangible measures for the reform of the WTO. Otherwise, we will also lose credibility. As many of the previous speakers have pointed out, it is high time we took practical steps in this direction."@en1
|
lpv:unclassifiedMetadata |
Named graphs describing this resource:
The resource appears as object in 2 triples